Iowa-based Wolfe Eye Clinic served as a primary contributor to a breakthrough vision-loss treatment recently approved by the U.S. Food and Drug Administration. The Phase III clinical trials were conducted at Wolfe Eye Clinic’s West Des Moines location, and on Oct. 8 the FDA announced approvals for Novartis Beovu, an alternative treatment for wet AMD (wet age-related macular degeneration). Wet AMD is a leading cause of severe vision loss and blindness in adults over 65. Until now, patients suffering from wet AMD would need eye injections as frequently as once a month. With the new treatment, patients may be able to extend the time between visits to as long as three months.